Daily Stock List
PTA Holdings, Inc. (PTAH)
PennyStocks24 and Top Stock Tips reported last week on PTA Holdings, Inc. (PTAH), WallstreetSurfers, PennyDoctor, TradeThesePicks did earlier, and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTC Pink Current Information, PTA Holdings, Inc. is a holding company with a core focus in the automotive industry. The Company is a multi-faceted transportation group providing an extensive spectrum of traditional transportation and management services. The Company acquired ProFlow, Inc. in 2007; they acquired Kingsley Logistic Group in 2012. PTA Holdings has their headquarters in Phoenix, Arizona.
Based in Georgia, ProFlow specializes in the research and development of lubrication products for the automotive and industrial transportation marketplace. ProFlow has their motor oil that the Company has branded "ProFlow 2030." This core motor oil product consists of a premium blend of paraffin and synthetic motor oils with proprietary additives, which substantially reduce friction in piston-fired cylinders, moving parts, gears and differentials. Consequently, this creates fuel savings of up to 30 percent.
The oil flows faster and reduces oil temperatures. The oil's flash points are double over other top brand name oils. They have ISO 9001 certification. ProFlow 2030 reduces internal wear and it reduces internal and external temperatures. This product reduces labor hours in companies for servicing machinery.
Kingsley Logistics Group is a comprehensive transportation group. They provide traditional transportation services such as LTL & Truckload, Inter-modal, Rail, Warehousing & Distribution, Equipment Leasing, Brokerage and 3PL, as well as Retail & Special Projects Business Groups.
Last week, PTA Holdings announced that the Company is in negotiations to purchase a Midwest trucker of ocean containers. This carrier services rail and port hubs situated in the States of Illinois and Wisconsin. They operate with company and owner/operator power, and company owned bogies. PTA Holdings' intention is to acquire more carriers and open more strategic terminals. The target carrier provides PTA with a strong start in the container business. PTA Holdings indicates that they will be able to expand the target's operating revenues of $2 million via addition of equipment.
PTA Holdings, Inc. (PTAH), closed Monday's trading session at $0.0007, down 22.22%, on 45,369,376 volume with 116 trades. The average volume for the last 60 days is 7,541,084 and the stock's 52-week low/high is $0.0004/$0.02.
Border Petroleum Corp. (BOR.V)
Today we are reporting on Border Petroleum Corp. (BOR.V), here at the QualityStocks Daily Newsletter.
Based in Calgary, Alberta, Border Petroleum Corp. is a junior oil and gas company whose shares trade on the TSX Venture Exchange. The Company concentrates on the development and exploitation of their light oil resource lands in the Red Earth area of north-central Alberta, and the Leduc area of central Alberta. Border Petroleum's growth strategy is to pursue Aboriginal partnerships (a vital part of their strategy) in balanced combination with strategic acquisitions and grassroots exploration and development.
The Company's oil focus is to develop high working interest (WI) core areas with considerable original oil in place (OOIP). Their focus is also to apply waterflood or horizontal drilling and multi-stage fracturing technologies to enhance recoveries and reserves.
Border Petroleum is actively developing and expanding their inventory of operated, high WI horizontal drilling opportunities on the Slave Point light oil resource play in the Red Earth/Evi area of north-central Alberta. Border has a 100 percent WI in 2,080 acres in this region.
The Company has a 5,320 net acre (8 1/3 sections) multi-zone light oil resource play in central Alberta. The primary zones are Leduc - D3 (1,650 m); Nisku - D2 (1,550 m); Wabamun - D1 (1,400 m), and Ellerslie/Detrital (1,300 m). These are all ideal for the application of horizontal well technology.
Border Petroleum's non-core areas include Norris, Cherhill, as well as Cardiff. Concerning Norris, the Company has WI's varying from 57.5 percent to 100 percent in 520 acres in the Norris area of central Alberta. This additionally consists of five producing oil wells, one water disposal well, as well as a central battery. Border has a 37.5 percent WI in 640 acres (240 net acres) in the Cherhill area of west central Alberta. Furthermore, the Company has a 100 percent WI in 160 acres in the Cardiff area of central Alberta; this consists of one Mannville oil well.
Border Petroleum Corp. (BOR.V), closed Monday's trading session at $0.015, up 20.00%, on 1,268,570 volume. The stock's 52-week low/high is $0.01/$0.22.
EnerTeck Corp. (ETCK)
Today we are highlighting EnerTeck Corp. (ETCK), here at the QualityStocks Daily Newsletter.
EnerTeck Corp., by way of their wholly owned subsidiary, EnerTeck Chemical Corp., specializes in the manufacture, sale and marketing of diesel fuel performance improvement catalysts and emission reduction technologies. The Company acquired EnerTeck Chemical Corp. (EnerTeck Sub) as a wholly owned subsidiary on January 9, 2003. Because of this acquisition, the Company is acting as a holding company, with EnerTeck Sub as their primary operating business. After 10 years of research and development, EnerTeck became operational in 2013 with their first major purchase orders. EnerTeck lists on the OTCQB. The Company has their headquarters in Stafford, Texas.
EnerTeck's injection equipment and flagship diesel fuel catalytic combustion accelerator product, EnerBurn®, have proven significant fuel savings, reduced emissions and prolonged engine life for large diesel operations in an assortment of industries globally. These include marine, ground transportation, mining, oil field services, fracking, military, government and public transit. EnerBurn® is a diesel fuel specific combustion catalyst, delivered to the engine through the diesel fuel, to improve the combustion rate of the fuel.
Additionally, EnerTeck introduced in 2012, and is now testing their PEx® (Particulate Extraction) product in anticipation of CARB (California Air Resources Board) approval this calendar year.
The Company has a number of new distributors and resellers in place in 2013. These include EnerGreen Technologies headquartered in Australia and with distribution networks in Southern Asia, Europe and South America. Distributors also include Jane Gates, Inc., a manufacturers' representative in oil and energy sales based in the Minneapolis area; Diesel Performance Teck, based in the greater Denver area, and Energy Information Works, an energy management-consulting firm based in New York, New York.
EnerTeck had $83,000 sales revenues for the three months ended March 31, 2013. This is in comparison to sales revenues of $0 for the three months ended March 31, 2012. The main source of revenue since 2011 has been from the sale of EnerBurn® to the oilfield service, heavy construction and maritime industries.
Gross profit was $69,000 or 82.9 percent for the three-month period ended March 31, 2013. This is in comparison with $0 or 0 percent of sales for the three-month period ended March 31, 2012. The Company reported a net loss of $356,000 during the three months ended March 31, 2013, versus a net loss of $342,000 for the three months ended March 31, 2012.
EnerTeck Corp. (ETCK), closed Monday's session at $0.39, up 129.41%, on 47,528 volume with 18 trades. The average volume for the last 60 days is 10,001 and the stock's 52-week low/high is $0.08/$0.79.
Lounor Exploration, Inc. (LO.V)
Vantage Wire and Green Chip Review reported previously on Lounor Exploration, Inc. (LO.V), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Lounor Exploration, Inc. engages in exploring and/or developing gold and base metal mining projects in the Abitibi Greenstone Belt. The Company has mineral holdings in the Canadian Provinces of Ontario and Quebec. The Abitibi Greenstone Belt is in both provinces of Ontario and Quebec with approximately 33 percent in Ontario and 67 percent in Quebec. Lounor Exploration lists on the TSX Venture Exchange. The Company has their corporate headquarters in Rouyn-Noranda, Quebec.
The Abitibi Greenstone Belt has produced greater than 180,000,000 ounces of gold, 450,000,000 tonnes of base metal ore over the last 100 years. Lounor Exploration's properties include Harker-Hurd - 100 percent option for 21 leased claims for 320 ha; Tiger - 50 percent option for 24 claims for 300 ha, and Queylus - 100 percent, 145 claims for 2320 ha. In addition, their properties include Trecesson - 100 percent for a block of 7 claims; Carqueville - 100 percent, 26 claims for 1040 ha, and Zinc (Bernières) - 100 percent for 16 units.
In early May, Lounor Exploration announced the closing of the transaction announced on March 22, 2013, following the approval of the TSX Venture Exchange on November 9, 2012. The transaction consists of the acquisition of 105 mining claims composing the Matagami Gold property. The Matagami Gold property is in the Matagami mining camp, Quebec. The Company has the option to acquire a 100 percent interest in 105 mining claims located in the Isle-Dieu Township, Quebec, covering a total area of 1,632 hectares.
Recently, Lounor Exploration announced that they closed a private placement for CDN $100,000. The placement consists in 2,000,000 common shares at a price of $0.05 per share representing $100,000 and of 1,000,000 share purchase warrants that give the right to subscribe for 1,000,000 additional common shares of the Company at a price of $0.10 per share, valid until May 21, 2014.
Lounor Exploration, Inc. (LO.V), closed Monday's trading session at $0.03, even for the day, on 26 volume. The stock's 52-week low/high is $0.03/$0.08.
Bio-Matrix Scientific Group, Inc. (BMSN)
PennyStocks24, PSNO.ORG, Bird Gang Stocks, Pennybuster, AwesomeStockPick, ExclusiveStockPick, Penny Lane Reports, PennyAuthority.com, ElitePennyStocks, Eastwind Research, Paradise Penny Stocks, Momentum Hunter, Penny King, VipStockReports, Pinnacle Stock Alerts, Leading Stock Alerts, and Stock Analyzer reported recently on Bio-Matrix Scientific Group, Inc. (BMSN), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.
Listed on the OTCQB, Bio-Matrix Scientific Group, Inc. (BMSN), through their wholly owned subsidiary, Regen BioPharma, Inc., is a biotechnology company headquartered in La Mesa, California. The Company focuses on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies via pre-clinical and Phase I/II clinical trials. Their Regen BioPharma is concentrating on developing translational medicine platforms for the rapid commercialization of stem cell therapies and to advancing intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the purpose of increased quality of life.
Regen BioPharma has assessed more than 20,000 stem cell related issued patents, narrowed down to 2,000 patents with commercial applicability. They have further identified 30 patents available for licensing. Regen BioPharma's areas of interest include Diabetes, Chronic Obstructive Pulmonary Disease (COPD), Heart Related illness, as well as Circulatory issues.
In early May, Regen BioPharma announced that they purchased patent #8,389,708 from Professor Wei-Ping Min of the University of Western Ontario - London, Ontario. This patent covers a novel means of stimulating the immune system against cancer through the blockade of a cancer specific molecular pathway (gene silencing). The acquired technology covers the use of RNA Interference to inhibit the enzyme indolamine 2,3 deoxygenase (IDO) specifically. In the patent and previous publication, Dr. Min and his team demonstrated that by blocking function of IDO, tumors would enter remission.
Last week, Regen BioPharma announced their submission of responses to the U.S. Food and Drug Administration's (FDA's) comments regarding their IND #15376 covering the use of HemaXellerate for treatment of immune suppressant resistant aplastic anemia. Regen BioPharma provided, as part of the response to comments, new data demonstrating efficacy of the HemaXellerate product at accelerating stem cell recovery after chemotherapeutic injury.
The HemaXellerate clinical trial is looking to recruit 10 patients with aplastic anemia that have not shown material signs of improvement under the current standard of care. If successful, Regen BioPharma will progress to larger efficacy-finding trials and expansion to other diseases that would benefit from enhancement of bone marrow stem cells.
Bio-Matrix Scientific Group, Inc. (BMSN), closed at $0.0023, even for the day, on 39,019,152 volume with 124 trades. The average volume for the last 60 days is 67,288,092 and the stock's 52-week low/high is $0.0002/$0.0165.
Nuvilex, Inc. (NVLX)
OTCJournal reported today on Nuvilex, Inc. (NVLX), PennyStocks24, SmallCapAllStars, TryBestPennyStocks.biz did last week, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Nuvilex, Inc. is a biotechnology and life technology company whose shares trade on the OTC Markets' OTCQB. The Company is a worldwide biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for the treatment of diseases. They engage in the development and marketing of products for enhancing the health and well-being of people globally.
Founded in 1996, they formerly went by the name eFoodSafety.com, Inc. They changed their name to Nuvilex, Inc. in March of 2009. The Company has their corporate headquarters in Silver Spring, Maryland.
Nuvilex provides live, therapeutically valuable, encapsulated cells and services for research and medicine. Their offerings will ultimately include cancer, diabetes and other treatments using the Company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently being developed.
Nuvilex is presently involved in cancer and diabetes research. The Company is preparing for a large-scale, late-phase clinical trial studying their treatment for patients with advanced, inoperable pancreatic cancer. In addition, Nuvilex is using the same basic technology to study diabetes. The technology is a unique and proprietary living cell encapsulation process. The basic technology has delivered promising results in the Company's pancreatic cancer trials.
Nuvilex announced earlier in 2013 that they are concentrating on positioning their subsidiary, Medical Marijuana Sciences, Inc., as a leader among entities in the medical marijuana field. This is by virtue of their goal of using Cannabis constituents in the development of treatments for brain and pancreatic cancer. Nuvilex is developing a treatment for advanced, inoperable pancreatic cancer, through their subsidiary Austrianova Singapore (ASPL). This involves using their proprietary cell encapsulation technology together with the well-known anticancer drug, ifosfamide.
Last week, Nuvilex reported that they have technology in their cell encapsulation process that they believe will very likely play some role in the future of oncology. The Company states that how large that role will be is dependent upon the technology continuing to return solid results when it is put to the test.
An area where the technology has had a chance to prove its worth is in a preclinical study reported in the scientific publication, International Journal of Cancer. In that study, the Company's cell encapsulation was used in tandem with the anticancer drug ifosfamide and radiation for the treatment of pancreatic tumors in rats. This study using Nuvilex's technology was to discover if the cell encapsulation/ifosfamide treatment could work on the preclinical level.
Nuvilex, Inc. (NVLX), closed today's session at $0.128, up 24.27%, on 3,339,162 volume with 325 trades. The average volume for the last 60 days is 3,731,574 and the stock's 52-week low/high is $0.019/$0.22.
Microelectronics Technology Co. (MELY)
Fast Moving Stocks, PennyStocks24, Penny Stock Rumble, Penny Trackers, InsideBulls, fusionspicks, RockingPennyStocks, Otcstockexchange, Whisper from Wall Street, and TryBestPennyStocks.biz reported recently on Microelectronics Technology Co. (MELY), and we are highlight the Company today, here at the QualityStocks Daily Newsletter.
Microelectronics Technology Co. is a cloud computing internet technology incubator. They offer cloud technology and services targeting small business. The Company acquired Cloud Data Corp. on August 26, 2011. Microelectronics Technology is based in Del Mar, California; the Company's shares trade on the OTC Markets' OTCQB.
Microelectronics Technology, via the acquisition of Cloud Data, is operating in the Internet incubator arena. This is to benefit from the technology opportunities available now and in the immediate future within the cloud-computing marketplace. In September of 2012, Cloud Data, the wholly owned subsidiary of Microelectronics Technology, signed WeatherCity Services as a Server Client. WeatherCity provides weather forecasts to over 62,000 cities in more than 121 countries using their unique computer forecasting system. Weather City is forecasting expansion in 2013 to 2 million cities with more than 30 million page views monthly.
In January 2013, Cloud Data announced the launch of their new Dedicated Server Hosting Platform. The Platform was created from the ground-up to meet the needs of modern dedicated server clients, with features that are distinct to the market. The Dynamo Servers Platform enables customers to construct private clouds and custom Platform as a Service (PaaS) solutions simply. Cloud Data is utilizing the platform to build their Sproq.com Platform as a Service offering.
Cloud Data announced this past February that they signed Wordpresshostingcanada.com to their Dynamo Servers product line. Wordpresshostingcanada.com has elected to use Dynamo Servers' Vancouver POP (Point Of Presence) as their main location to serve the Canadian market. Dynamo Servers supply dedicated servers to clients by way of their POP in Vancouver, inside a carrier neutral facility owned and operated by Cologix, Inc.
Recently, Microelectronics Technology announced the establishment of a dedicated sales and marketing division for their Dynamo Server subsidiary. The Sales and Marketing division will operate from the Company's U.S. corporate office. This will allow for the expansion of the Dynamo Server business model to include additional U.S. Points of Presence in Dallas and Chicago over the next two quarters.
Microelectronics Technology Co. (MELY), closed Monday's trading session at $0.007, up 27.27%, on 619,184 volume with 6 trades. The average volume for the last 60 days is 328,174 and the stock's 52-week low/high is $0.0047/$0.05.
TAG Oil Ltd. (TAOIF)
The Street and Investor Ideas reported previously on TAG Oil Ltd. (TAOIF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
TAG Oil Ltd. is a production and exploration company whose shares trade on the OTCQX International. The Company's operational focus is exclusively in New Zealand. Established in 2002, TAG at that time embarked on a strategic initiative to acquire projects in New Zealand. Now, in 2013, the Company is pursuing new exploration opportunities in the high-impact Kapuni Formation and the extensive East Coast. TAG Oil has their corporate headquarters in Vancouver, British Columbia.
The Company has 100 percent ownership over all their core assets. These include widespread oil and gas production infrastructure. TAG is experiencing considerable oil and gas production and reserve growth via development of a number of light oil and gas discoveries. Moreover, the Company is drilling high-impact exploration prospects identified across over 2,984,171 net acres of land in New Zealand.
TAG (in the East Coast Basin) is exploring the major unconventional resource potential believed to exist in the source-rock formations that are extensive over their acreage. These formations are oil-rich and naturally fractured. They have numerous similarities to North America's Bakken source-rock formation in the Williston Basin.
The Company is focusing their operations in the Taranaki and East Coast Basins of New Zealand's North Island, and the Canterbury Basin on the South Island. Their activities include oil and gas production in the Taranaki Basin, development of a number of discoveries, production infrastructure and high-impact exploration drilling across significant acres of land prospective for discovery at several play levels.
TAG is in the early stages of exploring the Canterbury Basin on New Zealand's South Island. This lightly explored frontier is geologically comparable to the productive Taranaki Basin and believed to contain substantial discovery potential.
In late May, TAG Oil announced that with the completion of their Taranaki Basin production facility expansion and associated pipeline, all but six wells capable of commercial production have now been tied into the facility and optimized for long-term production.
All production facilities are 100 percent owned and operated by the Company. They are now in place, and TAG is now able to quickly commercialize any new discoveries and take advantage of their strong Taranaki-region operational position.
TAG Oil Ltd. (TAOIF), closed Monday's trading session at $3.397, up 9.94%, on 132,426 volume with 246 trades. The average volume for the last 60 days is 37,321 and the stock's 52-week low/high is $2.675/$8.456.
Rainbow Coral Corp. (RBCC)
The QualityStocks Daily Newsletter would like to spotlight Rainbow Coral Corp. (RBCC). Today, Rainbow Coral Corp. closed trading at $0.30, up 7.14%, on 100,190 volume with 38 trades. The stock’s average daily volume over the past 60 days is 318,891, and its 52-week low/high is $0.10/$3.60.
Rainbow Coral Corp. reported today that they are pushing forward full speed ahead with an aggressive expansion strategy for 2013, including consideration of promising new funding opportunities that will aide in delivering the company's cutting-edge innovations to the $232B personalized medicine market. The recently signed JV with TheraKine Ltd.., who has developed a revolutionary sustained-release drug delivery platform that promises to make local delivery of biologic agents and small molecules much safer was emphasized, along with RBCC’s partnership to n3D and some of the other promising biotech initiatives the company has embarked on.
Rainbow Coral Corp. (RBCC), via wholly owned subsidiary Rainbow Biosciences, continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. The company specifically pursues opportunities that offer short-term marketability and commercialization potential in key areas like Alzheimer's, Parkinson's, and Cancer.
Bioscience technology is a growing, dynamic field of innovation that applies life processes to practical uses, such as the manufacturing of medical devices and the development of new bioscience procedures. From pharmaceuticals to pacemakers, genetically engineered plants to gene therapy, bioscience technology can be found virtually anywhere.
The pending joint venture with Amarantus BioScience to develop and market new therapies and treatments for neurological diseases and physical traumas is a great example of the initiatives underway. In recent news, Amarantus licensed a highly promising diagnostic blood test that could become an invaluable new tool in Alzheimer's clinical trials where patient recruitment errors occur often due to inaccurate diagnosis.
The global biotech industry, currently valued at more than $84.6B, allows new players with bright ideas to quickly grab market share and create completely new markets. The exciting initiatives being driven forward by Rainbow Coral promise to transition today's leading-edge research into practical, affordable treatments for people who need them most. Disclaimer
Rainbow Coral Corp. Company Blog
Rainbow Coral Corp. News:
RBCC Explores New Funding for Expansion
RBCC Poised To Gain Share Of $142 Billion Market
RBCC to Drive Growth Through Personalized Medicine
Advaxis, Inc. (ADXS)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.048, off by 4.00%, on 1,325,150 volume with 91 trades. The stock’s average daily volume over the past 60 days is 2,007,988, and its 52-week low/high is $0.0275/$0.155.
Advaxis Inc. reported issuance today of a letter to stockholders, strongly urging a positive response to Proposals No. 2 and No. 3 of the definitive proxy statement filed with the SEC on Schedule 14A this past April 30. The letter maps out the company's rationale in great detail, showing stockholders a clear path forward and strongly persuading them to approve the proposals, which would give this young biotech the crucial capital needed to fully implement the commercialization of its promising drug candidates.
Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis Issues Letter Advising Stockholders to Vote FOR Proposals 2 and 3 of Proxy Statement
Advaxis Requests Orphan Drug Designation for Treatment of Cervical Cancer with ADXS-HPV
Advaxis Announces Withdrawal of Proxy Statement Proposal to Amend Its Incentive Plan at This Time
Cardium Therapeutics, Inc. (CXM)
The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.09, up 18.42%, on 194,040 volume with 98 trades. The stock’s average daily volume over the past 60 days is 531,180, and its 52-week low/high is $0.06/$0.28.
Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.
The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.
Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer
Cardium Therapeutics, Inc. Company Blog
Cardium Therapeutics, Inc. News:
Cardium Announces Initial Voting Results And Temporary Adjournment of Annual Meeting To Be Reconvened On June 21, 2013
Cardium Announces Favorable Recommendations From ISS And Glass Lewis For Annual Meeting Proposals
Cardium Presents First Quarter 2013 Financial Results And Reports On Recent Developments
Mabwe Minerals Inc. (MBMI)
The QualityStocks Daily Newsletter would like to spotlight Mabwe Minerals Inc. (MBMI). Today, Mabwe Minerals Inc. closed trading at $0.021, up 5.00%, on 33,290 volume with 10 trades. The stock’s average daily volume over the past 60 days is 7,041, and its 52-week low/high is $0.0056/$0.25.
Mabwe Minerals Inc. (MBMI) is a U.S. based natural resources and hard asset company focused on the mining, logistics, and commercial sales of industrial minerals and metals, with a particular emphasis on barite. The company's operations are conducted through its Zimbabwe affiliate, Mabwe Mineral Zimbabwe (Private) Ltd. Transitioning into commercial production, MBMI's company fundamentals are well positioned with virtually no debt and key strategic partnerships in place.
Along with its affiliate, Mabwe Minerals Zimbabwe (Private) Ltd., an indigenous Zimbabwe company, the company owns 100% of the mineral & metal rights to Dodge Mine. The mine will be managed by the company's minority owned partner, WGB Kinsey & Company, Zimbabwe's most experienced mining & construction company representing four generations of Kinsey leadership. Management believes WGB Kinsey & Company has all the necessary equipment and management experience to efficiently perform all the mining operations at Dodge Mine.
The Dodge Mine property consists of three hydrothermal mountains representing 123 hectares containing multiple deposits of superior-grade barite, limestone, and talc. Hydrothermal barite deposits throughout Dodge Mine represent the highest grade of new barite sources to be brought into commercial production in years. A third party oil & gas drilling sector geologist recently confirmed that the multiple barite deposits are considered "World Class" in quality and highly efficient to mine via open pit extraction following the barite veins and salvaging large percentages of barite within the halo zones via jigging systems.
With a continuing worldwide shortage of high-grade barite, Mabwe Minerals is in the right place at the right time. The company's current customer uses barite as a weighting agent in oil & gas drilling applications in the Gulf of Mexico, home to the largest concentration of active rigs in the world. Coupled with the recent massive discovery of oil & gas off the coast of neighboring Mozambique along with new drilling contracts expected in the region, MBMI is in an attractive geographical location to capture the expected demands of this emerging market. Moving from an exploration stage company into commercial barite production, Mabwe Minerals is well positioned to generate significant shareholder returns. Disclaimer
Mabwe Minerals Inc. Company Blog
Mabwe Minerals Inc. News:
Mabwe Minerals Inc. Announces Engagement of QualityStocks Investor Relations Services
Mabwe Minerals Shareholder Report Card
Mawbe Minerals Files SEC Form 10-K, Annual Report
Rainbow Coral Corp. today told investors that it is considering new funding opportunities with promise in order to expand in the $232 billion personalized medicine market.
The company is pushing forward with its aggressive expansion strategy for this year and is already poised for rapid growth. The company recently signed a joint venture agreement with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective, and more convenient than ever before, and is currently in negotiations to partner with an emerging innovator in the transdermal delivery sector, as well. Last month, RBCC’s joint venture partner, Nano3D BioSciences, announced a distribution agreement with St. Louis-based scientific products distributor MIDSCI to sell its revolutionary BioAssembler product line in the multi-billion-dollar U.S biotechnology market.
“Our company is now well-positioned in a robust marketplace, and new funding opportunities are opening up for us every day,” said RBCC CEO Patrick Brown. “We’re carefully considering our options in order to ensure that we’re able to accomplish the goals that we’ve set for ourselves this year.”
Focused on expanding its marketing and development efforts, RBCC is fully committed to capitalizing on the unprecedented rise of the biotechnology sector.
For more information on RBCC’s partnership with n3D and other biotech initiatives, visit www.rainbowbiosciences.com/investors.html.
Advaxis, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, earlier today issued a letter to stockholders recommending that they vote ‘FOR’ Proposals No. 2 and No. 3 of its definitive proxy statement on Schedule 14A as filed with the SEC. The letter provides shareholders with compelling reasons why these proposals are in their best interests.
The full text of the letter follows:
Dear Fellow Stockholders,
We are writing to urge you to vote in favor of our current proxy proposals. Why? The answer is simple. We currently do not have steady access to financing that is efficient and will enable the Company to fully implement the commercialization of its drug candidates. And it is this work that is essential to bring the returns you expect from a biotech with very promising science.
Last year, for the first time, we encountered significant difficulties in raising capital to meet the cost of our clinical programs and the day to day costs of a dozen-employee company. And the capital that we were able to raise was highly dilutive to the Company’s stockholders.
We worked very hard to obtain that financing to keep our Company going and, while we had success, it was not sufficient to support the business for the long term. Our liquidity issues were reflected in our Form 10-K for our fiscal year ended October 31, 2012 (which reported that we had $232 on hand at the end of the fiscal year) and our stock price (which closed at $0.03 per share on the last day of the calendar year).
We believe this situation has suppressed our stock and made our Company less attractive to new stockholders. While 2013 has been better, the fundamental situation is unchanged.
Our recent financing experience has brought us into a position that is typical for an early stage biotech company. Nevertheless, with the capital that we were able to raise, we have been able to conduct successful clinical trials and continue to develop valuable intellectual property. Importantly, we are now positioned as a candidate for up-listing to a national market, such as NASDAQ. Many development stage companies fail to reach this point.
We’ve explained in our recent filings why up-listing to a national market is important to our Company and our overall business strategy. We write now to emphasize that this is the single most important means to gain access to additional sources of capital, namely “institutional” investors who currently will not invest in our Company because we are traded on the OTC and are a “penny-stock.” The second benefit is to be better positioned to secure research coverage for our Company, which can leverage our great science. If we are not able to obtain a listing on a national market, then we will of course continue to raise capital in our historical fashion. But it will, in our judgment, be more dilutive than the course we recommend: to implement a reverse stock split and up-list onto a national market in connection with the proposed capital raise.
Our goal is to raise funds at a minimum dilution for our stockholders. You know that, for a biotech, dilution is inevitable and essential. Early investors, like your management, put cash into a company anticipating that a scientific concept would multiply in value as it is developed into a potentially life-saving or life-extending drug. New money feeds that value generation process. Even licensing is another form of dilution, as future value is exchanged for cash and lower development costs that in turn require that less capital be raised.
We strongly believe that the decision to undertake the proposed capital raise and up-list to a national market, both of which will be enabled by a vote in favor of proxy Proposals No. 2 and No. 3, are the best strategic move for, and in the best interests of, stockholders. We will use the new dollars to further develop ADXS-HPV and we believe it will increase the value of the Company at a much higher rate than the cost of capital and, therefore, translate into an increase in the value of our stock.
Obviously, the choice is yours. We’ve worked hard to get the Company to this point. We believe that our stockholders will understand that this is what we consider to be the best path — perhaps the only long-term sustainable one — for our Company.
Few biotech companies survive this long. We have done so through the unwavering support of you, our stockholders. By this letter, we hope that you will understand the motivation for our proposals and can make a fully informed decision of your own. The Board of Directors and management of the Company strongly urge stockholders to vote in favor of Proposals No. 2 and No. 3 related to the Company’s certificate of incorporation.
If you have already voted “for” these proposals in the earlier proxy, you do not need to again vote “for” these proposals.
If you previously voted “against” these proposals you may change your vote by telephone, by Internet, or by mail.
If you need assistance voting your shares, please contact our proxy solicitor, Morrow & Co., LLC at 855-231-8973.
Thomas A. Moore
Chairman & Chief Executive Officer
For more information on Advaxis, visit www.advaxis.com
Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription products. The company’s primary target markets include hospital acute care and gastroenterology. Its product portfolio includes Kristalose (prescription laxative), Caldolor injection (treatment for pain and fever), and Acetadote injection for treatment of acetaminophen poisoning.
The company announced today that the U.S. Food and Drug Administration (FDA) has approved updated labeling for Acetadote injection. Acetadote is currently used in hospital emergency departments to prevent or lessen potential liver damage resulting from an overdose of acetaminophen, a common ingredient in many pain killers, both prescription and over-the-counter. Acetaminophen remains one of the leading causes of poisoning in the U.S.
The new labeling revises the indication for Acetadote and offers new dosing guidance for specific populations. The new indication states, “Acetadote is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen.” The new wording for Acetadote eliminated the confusion about concerning efficacy when a dose was not administered within 8 to 10 hours. Specific dosing is now included for patients weighing over 100 kilograms.
Acetadote does not contain ethylene diamine tetracetic acid (EDTA) or any other stabilization or chelating agents and is free of preservatives. Cumberland’s current updated formulation has a longer shelf life of 30 months. For additional information about Acetadote, go to www.acetadote.com. For a look at Cumberland Pharmaceuticals’ entire product line, please visit www.cumberlandpharmca.com.
Verenium announced today that Brian Carter, an enzyme industry veteran, has been appointed as its Vice President of Grain Processing.
Carter joined the company in September 2012 as Vice President, Business Development. Prior to Verenium, Mr. Carter spent nearly 20 years at Genencor, now part of DuPont Industrial Biosciences. He held a variety of senior leadership roles at Genecor in business development and general management.
Carter’s appointment is the latest in a series of organizational enhancements Verenium has made to expand its presence in the grain processing industry; Kulinda Davis, Ph.D., has assumed the role of Director, Business Strategy and Marketing, focused on supporting further penetration of the U.S. market, commercializing new enzyme products, and expanding Verenium’s international presence in grain processing. The company has also made key hires in sales, field technical support, and in-house customer technical support.
Janet Roemer, Verenium’s COO, commented, “Brian and Kulinda’s appointments are important steps in building a world class team to support our customers in the U.S. corn ethanol market and in growing our presence in the global grain processing industry.”
Today's Top 3
Wall Street Resources
Penny Stock Beats
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Advaxis, Inc. (ADXS) Issues Letter Advising Stockholders to Vote FOR Proposals 2 and 3 of Proxy Statement
- Consorteum Holdings, Inc. (CSRH) Enters Partnership Agreement With KO Entertainment, Inc.
- Cardium Therapeutics, Inc. (CXM) Announces Initial Voting Results And Temporary Adjournment of Annual Meeting To Be Reconvened On June 21, 2013
- DoMark International, Inc. (DOMK) Engages Leading Global Designer to Develop a New Luxury Range of Accessory Products for the Apple iPad for the $200 Billion Luxury Product Market
- GNCC Capital, Inc. (GNCP) Nears Completion of the Acquisition of the White Hills Gold Properties
- GlobalWise Investments, Inc. (GWIV) Adds Toshiba Business Solutions AZ/CO as New Channel Sales Partner
- International Stem Cell Corp. (ISCO) Initiates IND-Enabling Study in Parkinson's Disease Program
- Loans4Less.com, Inc. (LFLS) CEOCFO Magazine Interview Highlights Solid Market Position
- Low Carbon Technologies International, Inc. (LWCTF) Plans to Announce 6 Month YTD Financials
- Mabwe Minerals Inc. (MBMI) Announces Engagement of QualityStocks Investor Relations Services
- Rafarma Pharmaceuticals, Inc. (RAFA) Enters $50M Ceftriaxone Market and Signs Long-Term National and Regional Distribution Contracts
- Rainbow Coral Corp. (RBCC) Explores New Funding for Expansion
- Raptor Resources Holdings Inc. (RRHI) Announces Engagement of QualityStocks Investor Relations Services
- Solar Wind Energy Tower, Inc. (SWET) CEO Featured in Exclusive QualityStocks Interview
- StreamTrack, Inc. (STTK) Announces Alliance to Potentially Reach Over 300 Million Registered PPTV Users
- The Aristocrat Group Corp. (ASCC) Targets August Sales Debut for RWB Ultra-Premium Gluten-Free Vodka
- The Guitammer Company Inc. (GTMM) Goes Supersonic!
- VentriPoint Diagnostics Ltd. (VPTDF) Announces New Vice-President of Sales and Marketing
- VistaGen Therapeutics, Inc. (VSTA) and Duke University Publish Results on Production of Functional 3D Human Heart Tissue